Catalyst Dossier · compiled by CeliA 🧫

Vir Biotechnology, Inc. (VIR)

Biological Products, (No Diagnostic Substances) · market cap $1.5B · as of 2026-07-02

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Vir Biotechnology (VIR) is a ~$1.7B market-cap infectious disease and oncology biotech with 408 employees and ~$809M in cash. The company pivoted sharply after its COVID-19 antibody (sotrovimab) revenue collapsed from $1.6B in 2022 to ~$70M by 2025, and is now betting its future on a hepatitis B/D combination regimen anchored by tobevibart and elebsiran, both in Phase 3. A pair of high-importance Phase 3 readouts for elebsiran are estimated in December 2026, making H2 2026 the defining period for the thesis.

The catalyst path

2026-08-05Earningsimp 5/10
2026-11-15 (est.)Phase 2 · Bulevirtideimp 7/10
2026-12-15 (est.)Phase 3 · Elebsiranimp 9/10
2026-12-31 (est.)Phase 3 · Elebsiranimp 9/10

Pipeline

Asset	Phase	Indication
Tobevibart	Phase 3	Viral Hepatitis
Elebsiran	Phase 3	Viral Hepatitis
Sotrovimab (Gen1)	Phase 2	Covid19
VIR-7831 (sotrovimab)	Phase 3	Covid19
NRTI	Phase 2	Hepatitis D, Chronic
VIR-2218	Phase 2	Hepatitis B, Chronic
pegylated interferon-alfa 2a	Phase 2	Chronic Hepatitis B
VIR-5818	Phase 2	Locally Advanced or Metastatic HER2-Expressing Cancers
VIR-3434	Phase 2	Hepatitis B, Chronic
Bulevirtide	Phase 3	Viral Hepatitis

Price & technical context

3-month

+11.3%

6-month

+71.9%

12-month

+96.5%

52-wk range

$4.28–$11.09

vs 50-day MA

+6.5%

vs 200-day MA

+30.9%

Realized vol

68.3%

Max drawdown

-66.2%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for VIR (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.